|
|
| | insulin glargine Basic information |
| Product Name: | insulin glargine | | Synonyms: | insulin glargine;Insulin Glargine EP/USP;A21-Gly-B31-Arg-B32-Arg-insulin;Insulin, glycyl(A21)-arginyl(B31,B32)-;Lantus;Solostar;Solostar [insulin delivery pen];Unii-2zm8cx04rz | | CAS: | 160337-95-1 | | MF: | C267H404N72O78S6 | | MW: | 6062.89026 | | EINECS: | | | Product Categories: | | | Mol File: | 160337-95-1.mol |  |
| | insulin glargine Chemical Properties |
| storage temp. | -20°C, Inert atmosphere | | solubility | Aqueous Acid (Very Slightly) | | form | Liquid | | color | White to Off-White | | Sequence | A-chain: Gly-Ile-Val-Glu-Gln-Cys-Cys-Thr-Ser-Ile-Cys-Ser-Leu-Tyr-Gln-Leu-Glu-Asn-Tyr-Cys-Gly; B-chain: Phe-Val-Asn-Gln-His-Leu-Cys-Gly-Ser-His-Leu-Val-Glu-Ala-Leu-Tyr-Leu-Val-Cys-Gly-Glu-Arg-Gly-Phe-Phe-Tyr-Thr-Pro-Lys-Thr-Arg-Arg (Disulfide bridge: CysA6-CysA11, CysA7-CysB7, CysA20-CysB19) | | InChIKey | COCFEDIXXNGUNL-RFKWWTKHSA-N | | CAS DataBase Reference | 160337-95-1 |
| WGK Germany | nwg | | HS Code | 2937120000 | | Storage Class | 11 - Combustible Solids |
| | insulin glargine Usage And Synthesis |
| Uses | long-acting basal insulin analogue, helping control the blood sugar level of those with type 1 and type 2 diabetes mellitus. It is an analogue of human insulin made by replacing the asparagine residue at position A21 of the A-chain with glycine and adding | | Uses | Insulin Glargine (>90%) is an insulin analogue used in the treatment of adults with type 1 or type 2 diabetes. | | Brand name | Lantus (Hoechst Marion Roussel). | | Biological Activity | Insulin glargine is an approved long-acting insulin analog used for management of Diabetes Type 1 and Type 2. Insulin glargine is a human insulin analog where A-chain asparagine 21 was replaced by glycine and B-chain carboxy terminal was extended by two arginine residues. | | in vivo | Insulin glargine (2-12.5 IU/kg; subcutaneous injection; 3-12 months) does not present a carcinogenic risk in rodents[2].
Insulin glargine (450 mg/kg; subcutaneous injection; 6 months) has an improving effect in a mouse model of diabetes[3]. | Animal Model: | Seven-week-old male db/db mice[3] | | Dosage: | 450 mg/kg | | Administration: | Subcutaneous injection (s.c.); 6 months | | Result: | Significantly improved glucose tolerance.
Upregulated pancreatic β-cell functional genes, such as INS1, Pdx1, Pax4 and Pax6.
|
|
| | insulin glargine Preparation Products And Raw materials |
|